
USD
+$0.00
(+0.00%
)At Close (As of Dec 11, 2025)
$23.05B
Market Cap
-
P/E Ratio
-2.78
EPS
$129.27
52 Week High
$81.20
52 Week Low
HEALTHCARE
Sector
| Field | Value (EUR) |
|---|---|
| Gross Profit | $2.2B |
| Total Revenue | $2.8B |
| Cost Of Revenue | $541M |
| Costof Goods And Services Sold | $541M |
| Operating Income | -$1.3B |
| Selling General And Administrative | $531M |
| Research And Development | $2.3B |
| Operating Expenses | $3.5B |
| Investment Income Net | - |
| Net Interest Income | $425M |
| Interest Income | $438M |
| Interest Expense | $13M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $298M |
| Income Before Tax | -$678M |
| Income Tax Expense | -$12M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$665M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$665M |
| Ebitda | -$367M |
| Net Income | -$665M |
| Field | Value (EUR) |
|---|---|
| Gross Profit | $2.2B |
| Total Revenue | $2.8B |
| Cost Of Revenue | $541M |
| Costof Goods And Services Sold | $541M |
| Operating Income | -$1.3B |
| Selling General And Administrative | $531M |
| Research And Development | $2.3B |
| Operating Expenses | $3.5B |
| Investment Income Net | - |
| Net Interest Income | $425M |
| Interest Income | $438M |
| Interest Expense | $13M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $298M |
| Income Before Tax | -$678M |
| Income Tax Expense | -$12M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$665M |
| Comprehensive Income Net Of Tax | - |
| Ebit | -$665M |
| Ebitda | -$367M |
| Net Income | -$665M |
| Field | Value |
|---|---|
| Ex Dividend Date | 2022-06-02 |
| Declaration Date | None |
| Record Date | None |
| Payment Date | None |
| Amount | 2.111 |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
BioNTech SE, headquartered in Mainz, Germany, is a pioneering biotechnology company at the forefront of developing and commercializing innovative immunotherapies aimed at addressing cancer and infectious diseases. Renowned for its rapid collaboration with Pfizer in bringing a transformative COVID-19 vaccine to market, BioNTech has established a robust pipeline focused on personalized cancer therapies and cutting-edge mRNA-based treatments. The company’s emphasis on precision medicine, combined with its strong commitment to scientific research and strategic alliances, positions BioNTech as a leader in the evolving biotechnology sector, poised to address significant unmet medical needs globally.